Proven across a broad range of complex cases, the versatility of the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface* enables you to deliver high patency and durable outcomes to minimize reinterventions. Consider the types of cases you treat and the challenges they present; the GORE® VIABAHN® Endoprosthesis helps you optimize clinical outcomes for your patients.
Arteriovenous (AV) access
The GORE® VIABAHN® Endoprosthesis has proven success in the most challenging AV access cases, including early percutaneous transluminal angioplasty (PTA) failures, lesions at points of flexion, and in thrombosed grafts
Designed to conform to challenging anatomy and proven to resist fractures**
Demonstrated patency independent of the number of prior interventions1
Increased primary patency in thrombosed grafts of both the target lesion and the circuit when compared to PTA1
Superficial femoral artery (SFA)
The GORE® VIABAHN® Endoprosthesis delivers strong clinical performance in the most challenging cases with 75% average primary patency demonstrated across five multicenter, prospective, randomized or single arm studies with an average lesion length of 22 cm and 72% chronic total occlusions (CTOs)2-6
Comparable clinical results to above knee surgical bypass (both prosthetic and native vein)2,7
Excellent patency and durability independent of lesion length2-6
In-stent restenosis (ISR) of the SFA
The GORE® VIABAHN® Endoprosthesis provides durable treatment for complex in-stent restenotic lesions
Ability to cover and seal disease, leading to durable outcomes in long, complex ISR
The GORE® VIABAHN® Endoprosthesis is the only self-expanding stent graft indicated to treat iliac lesions
The GORE® VIABAHN® Endoprosthesis family has demonstrated patency that approaches surgical bypass8-10
Popliteal artery aneurysm (PAA)
The GORE® VIABAHN® Endoprosthesis shows strong clinical performance in challenging PAA cases
Endovascular repair of popliteal aneurysms is associated with acceptable long-term patency and a very low risk of limb loss11
* As used by Gore, Heparin Bioactive Surface refers to Gore’s proprietary CBAS Heparin Surface.
** Across all uses, the GORE® VIABAHN® Endoprosthesis has a reported fracture rate of < .015% (data on file 2018; W. L. Gore & Associates, Inc; Flagstaff, AZ.)
1. Vesely T, DaVanzo W, Behrend T, Dwyer A, Aruny J. Balloon angioplasty versus Viabahn stent graft for treatment of failing or thrombosed prosthetic hemodialysis grafts. Journal of Vascular Surgery 2016;64(5):1400-1410.e1. http://www.sciencedirect.com/science/article/pii/S0741521416301756
2. Reijnen M, van Walraven L, Fritschy W, et al. 1-year results of a multicenter, randomized controlled trial comparing heparin-bonded endoluminal to femoropopliteal bypass. Journal of Cardiovascular Interventions 2107;10(22):2320-2331.
3. Ohki T, Kichikawa K, Yokoi H, et al. Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions. Journal of Vascular Surgery 2017;66(1):130-142.e1.
4. Saxon RR, Chervu A, Jones PA, et al. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin-bonded Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) Trial. Journal of Vascular & Interventional Radiology 2013;24(2):165173.
5. Lammer J, Zeller T, Hausegger KA, et al. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR Trial. Cardiovascular & Interventional Radiology 2015;38(1):25-32.
6. Zeller T, Peeters P, Bosiers M, et al. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm Trial. Journal of Endovascular Therapy 2014;21(6):765-774.
7. McQuade K, Gable D, Pearl G, Theune B, Black S. Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. Journal of Vascular Surgery 2010;52(3):584-591.
8. Lammer J, Dake MD, Bleyn J, et al. Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent graft. Radiology 2000;217(1):95-104.
9. Bismuth J, Gray BH, Holden A, Metzger C, Panneton J; VBX FLEX Study Investigators. Pivotal study of a next-generation balloon-expandable stent-graft for treatment of iliac occlusive disease. Journal of Endovascular Therapy 2017;24(5):629-637. http://journals.sagepub.com/doi/full/10.1177/1526602817720463
10. Indes JE, Pfaff MJ, Farrokhyar F, et al. Clinical outcomes of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac occlusive disease: a systematic review and meta-analysis. Journal of Endovascular Therapy 2013;20(4):443-455.
11. Golchehr B, Zeebregts CJ, Reijnen MMPJ, Tielliu IFJ. Long-term outcome of endovascular popliteal artery aneurysm repair. Journal of Vascular Surgery 2018;67(6):1797-1804.